Sponsors across therapeutic areas including vaccines, rare disease, advanced therapies and biosimilars have been increasingly turning to the Asia-Pacific (APAC) region for solutions to overcome some of the key challenges of complex clinical trials across development phases. Our panel will discuss the region’s outstanding infrastructure, site capabilities, untapped patient populations, favorable regulatory environment, and biotech R&D incentives for early phase studies and how APAC provides a solution. Panelists will also discuss common concerns of US and European sponsors including data integrity, acceptance of study data by the FDA and EMA, trial diversity and recommendations to effectively collaborate across the globe.